ClinicalTrials.gg
CompletedNCT02260882Updated Oct 30, 2018Results posted

Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)

A Phase 4 interventional study of PNEUMOVAX™ 23 in Pneumococcal Infection, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 70 Years to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
243
Allocation
Non-randomized
Ages
70 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections — 1 open to participants now, 1 under way, 1 of them phase 3. 23-valent pneumococcal capsular polysaccharide vaccine · Pneumococcal Infections.

Enrollment
8th of 15
243 · median 243
Started
2014
with 3 others
Phase 4
5 of 15
none open now
Registered
9th of 15
by date
Lead sponsor
5 of 15
Merck Sharp & Dohme LLC

Among the 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections, this one is the 8th largest by enrollment, is one of 4 that started in 2014, is one of 5 in phase 4, and was the 9th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

1 of the 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 23-valent pneumococcal capsular polysaccharide vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 70 Years to 89 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

The purpose of this study is to determine if revaccination with pneumococcal vaccine (PNEUMOVAX™ 23, V110) is well tolerated and produces an immune response in older Japanese adults. The primary hypothesis being tested is that the geometric mean concentration of antibodies to pneumococcal polysaccharide serotypes 3, 6B, and 23F at 4 weeks after revaccination will be superior to that before revaccination in Japanese adults who received a primary vaccination at least 5 years before revaccination.

03

Conditions studied

  • Pneumococcal Infection
04

Who can participate

Ages eligible
70 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Japanese participant
  • Good health or any underlying chronic illness is documented to be in stable condition
  • Revaccination Group: received one documented PNEUMOVAX™ 23 vaccination at least 5 years before enrollment in the study
  • Primary Vaccination Group: no prior history with PNEUMOVAX™ 23 vaccination Exclusion Criteria:
  • Known allergy or sensitivity to any of the components of the study vaccine
  • History of pneumococcal conjugate vaccination
  • Known or suspected immune dysfunction, , or disease. Participants with a history of cancer who are not actively treated and not immunosuppressed will be eligible
  • Functional or anatomic asplenia
  • Received immunoglobulin within 6 months before study vaccine or is planned during the study
  • Received any drugs or vaccines within 2 months before study vaccination
  • History of pneumococcal disease (positive culture from blood or other normally sterile site)
  • Thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection
  • History of convulsion
  • Previously diagnosed with immunodeficiency or has a close relative with congenital immune deficiency
  • Participating in any other clinical trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
243 participants (actual)

Study arms

  • Experimental
    Revaccination Group

    0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who received an initial vaccination at least 5 years prior

    Biological: PNEUMOVAX™ 23

  • Experimental
    Primary Vaccination Group

    0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who have never received PNEUMOVAX™ 23 vaccination

    Biological: PNEUMOVAX™ 23

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Serotype-Specific Antibody Geometric Mean Concentration at 4 Weeks After Revaccination

    Serum antibodies to pneumococcal serotypes were measured by enzyme-linked immunosorbent assays. Geometric mean antibody concentrations (GMCs) were calculated at Baseline and 4 weeks postvaccination. Geometric Mean Fold Rise was the GMC at 4 weeks after vaccination minus the GMC at Baseline.

    Time frame: Baseline and 4 weeks after revaccination

Secondary outcomes

  1. Change From Baseline in Serotype-Specific Antibody Geometric Mean Concentration at 4 Weeks After Primary Vaccination

    Serum antibodies to pneumococcal serotypes were measured by enzyme-linked immunosorbent assays. Geometric mean antibody concentrations (GMCs) were calculated at Baseline and 4 weeks postvaccination. Geometric Mean Fold Rise was the GMC at 4 weeks after vaccination minus the GMC at Baseline.

    Time frame: Baseline and 4 weeks after primary vaccination

  2. Percentage of Participants With an Adverse Event of Injection-site Erythema

    An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of injection-site erythema recorded on the Vaccine Report Card (VRC) during the first 5 days after vaccination was recorded.

    Time frame: Up to 5 days after vaccination

  3. Percentage of Participants With an Adverse Event of Injection-site Swelling

    An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of injection-site swelling recorded on the VRC during the first 5 days after vaccination was recorded.

    Time frame: Up to 5 days after vaccination

  4. Percentage of Participants With an Adverse Event of Injection-site Pain

    An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of injection-site pain recorded on the VRC during the first 5 days after vaccination was recorded.

    Time frame: Up to 5 days after vaccination

  5. Percentage of Participants With an Adverse Event of Pyrexia

    Percentage of participants with an adverse event of pyrexia (\>=37.5°C, oral) recorded on the VRC during the first 5 days after vaccination was recorded.

    Time frame: Up to 5 days after vaccination

  6. Percentage of Participants With an Adverse Event of Myalgia

    An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of myalgia recorded on the VRC during the first 14 days after vaccination was recorded.

    Time frame: Up to 14 days after vaccination

  7. Percentage of Participants With an Adverse Event of Arthralgia

    An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of arthralgia recorded on the VRC during the first 14 days after vaccination was recorded.

    Time frame: Up to 14 days after vaccination

  8. Percentage of Participants With an Adverse Event of Headache

    An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of headache recorded on the VRC during the first 14 days after vaccination was recorded.

    Time frame: Up to 14 days after vaccination

  9. Percentage of Participants With an Adverse Event of Fatigue

    An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of fatigue recorded on the VRC during the first 14 days after vaccination was recorded.

    Time frame: Up to 14 days after vaccination

07

Results

Posted Feb 17, 2016

Participant flow

Participant flow — Overall Study
MilestoneRevaccination GroupPrimary Vaccination Group
Started16182
Completed16181
Not completed01
Withdrew: Protocol violation01

Outcome measures

PrimaryChange From Baseline in Serotype-Specific Antibody Geometric Mean Concentration at 4 Weeks After Revaccination

Serum antibodies to pneumococcal serotypes were measured by enzyme-linked immunosorbent assays. Geometric mean antibody concentrations (GMCs) were calculated at Baseline and 4 weeks postvaccination. Geometric Mean Fold Rise was the GMC at 4 weeks after vaccination minus the GMC at Baseline.

Time frame:
Baseline and 4 weeks after revaccination
Reported as:
Geometric mean · Geometric Mean Fold Rise
Change From Baseline in Serotype-Specific Antibody Geometric Mean Concentration at 4 Weeks After Revaccination
Geometric Mean Fold RiseRevaccination Group
Serotype 3: n=1612.72 (2.35 to 3.14)
Serotype 6B: n=1612.27 (2.02 to 2.55)
Serotype 23F: n=1602.40 (2.12 to 2.72)
Statistical analysis
  • Revaccination Group · t-test, 1 sided · p = <0.001
  • Revaccination Group · t-test, 1 sided · p = <0.001
  • Revaccination Group · t-test, 1 sided · p = <0.001
SecondaryChange From Baseline in Serotype-Specific Antibody Geometric Mean Concentration at 4 Weeks After Primary Vaccination

Serum antibodies to pneumococcal serotypes were measured by enzyme-linked immunosorbent assays. Geometric mean antibody concentrations (GMCs) were calculated at Baseline and 4 weeks postvaccination. Geometric Mean Fold Rise was the GMC at 4 weeks after vaccination minus the GMC at Baseline.

Time frame:
Baseline and 4 weeks after primary vaccination
Reported as:
Geometric mean · Geometric Mean Fold Rise
Change From Baseline in Serotype-Specific Antibody Geometric Mean Concentration at 4 Weeks After Primary Vaccination
Geometric Mean Fold RisePrimary Vaccination Group
Serotype 34.01 (3.17 to 5.08)
Serotype 6B5.83 (4.41 to 7.69)
Serotype 23F6.11 (4.65 to 8.02)
SecondaryPercentage of Participants With an Adverse Event of Injection-site Erythema

An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of injection-site erythema recorded on the Vaccine Report Card (VRC) during the first 5 days after vaccination was recorded.

Time frame:
Up to 5 days after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With an Adverse Event of Injection-site Erythema
Percentage of participantsRevaccination GroupPrimary Vaccination Group
Percentage of Participants With an Adverse Event of Injection-site Erythema35.414.8
SecondaryPercentage of Participants With an Adverse Event of Injection-site Swelling

An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of injection-site swelling recorded on the VRC during the first 5 days after vaccination was recorded.

Time frame:
Up to 5 days after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With an Adverse Event of Injection-site Swelling
Percentage of participantsRevaccination GroupPrimary Vaccination Group
Percentage of Participants With an Adverse Event of Injection-site Swelling38.517.3
SecondaryPercentage of Participants With an Adverse Event of Injection-site Pain

An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of injection-site pain recorded on the VRC during the first 5 days after vaccination was recorded.

Time frame:
Up to 5 days after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With an Adverse Event of Injection-site Pain
Percentage of participantsRevaccination GroupPrimary Vaccination Group
Percentage of Participants With an Adverse Event of Injection-site Pain62.746.9
SecondaryPercentage of Participants With an Adverse Event of Pyrexia

Percentage of participants with an adverse event of pyrexia (\>=37.5°C, oral) recorded on the VRC during the first 5 days after vaccination was recorded.

Time frame:
Up to 5 days after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With an Adverse Event of Pyrexia
Percentage of participantsRevaccination GroupPrimary Vaccination Group
Percentage of Participants With an Adverse Event of Pyrexia6.81.2
SecondaryPercentage of Participants With an Adverse Event of Myalgia

An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of myalgia recorded on the VRC during the first 14 days after vaccination was recorded.

Time frame:
Up to 14 days after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With an Adverse Event of Myalgia
Percentage of participantsRevaccination GroupPrimary Vaccination Group
Percentage of Participants With an Adverse Event of Myalgia0.00.0
SecondaryPercentage of Participants With an Adverse Event of Arthralgia

An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of arthralgia recorded on the VRC during the first 14 days after vaccination was recorded.

Time frame:
Up to 14 days after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With an Adverse Event of Arthralgia
Percentage of participantsRevaccination GroupPrimary Vaccination Group
Percentage of Participants With an Adverse Event of Arthralgia0.00.0
SecondaryPercentage of Participants With an Adverse Event of Headache

An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of headache recorded on the VRC during the first 14 days after vaccination was recorded.

Time frame:
Up to 14 days after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With an Adverse Event of Headache
Percentage of participantsRevaccination GroupPrimary Vaccination Group
Percentage of Participants With an Adverse Event of Headache1.91.2
SecondaryPercentage of Participants With an Adverse Event of Fatigue

An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. Percentage of participants with an adverse event of fatigue recorded on the VRC during the first 14 days after vaccination was recorded.

Time frame:
Up to 14 days after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With an Adverse Event of Fatigue
Percentage of participantsRevaccination GroupPrimary Vaccination Group
Percentage of Participants With an Adverse Event of Fatigue1.20.0

Adverse events

Collected over All adverse events: up to 14 days after vaccination; deaths and vaccine-related serious adverse events: up to 36 days after vaccination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Revaccination Group—4/161 (2.5%)113/161 (70.2%)
Primary Vaccination Group—0/81 (0%)41/81 (50.6%)
Most frequent serious events
Most frequent serious events
EventRevaccination GroupPrimary Vaccination Group
PyrexiaGeneral disorders1/1610/81
Herpes virus infectionInfections and infestations1/1610/81
Femoral neck fractureInjury, poisoning and procedural complications1/1610/81
Bronchitis chronicRespiratory, thoracic and mediastinal disorders1/1610/81
Most frequent other events
Most frequent other events
EventRevaccination GroupPrimary Vaccination Group
Injection-site painGeneral disorders101/16138/81
Injection-site swellingGeneral disorders62/16114/81
Injection-site erythemaGeneral disorders57/16112/81
Injection-site pruritusGeneral disorders11/1612/81
PyrexiaGeneral disorders11/1611/81

Baseline characteristics

One participant in the Primary Vaccination Group was withdrawn from the study before vaccination because of a protocol violation. Baseline Characteristics are based on the Full Analysis Set: participants who received at least one vaccination.

Age, Continuous
Age, Continuous(Years)Revaccination GroupPrimary Vaccination GroupTotal
Mean78.8 ± 4.878.2 ± 5.078.6 ± 4.8
Sex: Female, Male
Sex: Female, Male(Participants)Revaccination GroupPrimary Vaccination GroupTotal
Female9446140
Male6735102
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kawakami K, Kishino H, Kanazu S, Toshimizu N, Takahashi K, Sterling T, Wang M, Musey L. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses. Vaccine. 2016 Jul 19;34(33):3875-81. doi: 10.1016/j.vaccine.2016.05.052. Epub 2016 Jun 10. PubMed 27265450 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Apr 2015, 5 months.

Results were first posted in Feb 2016, 10 months after primary completion.

Of 21 phase 4 interventional studies under Pneumococcal Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 44. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2014
First posted
Oct 9, 2014
StartActual
Oct 31, 2014
Primary completionActual
Apr 9, 2015
CompletionActual
Apr 9, 2015
Results first posted
Feb 17, 2016
Last update
Oct 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02260882
Responsible party
Sponsor
First posted
Oct 9, 2014
Start date
Oct 31, 2014
Primary completion
Apr 9, 2015
Completion
Apr 9, 2015
Results posted
Feb 17, 2016
Last update
Oct 30, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 23-valent pneumococcal capsular polysaccharide vaccine

Start the discussion